Sanat Mishra

Timeline

1. MumbaiGrows up in Mumbai, where he says he is from, before leaving for a science degree at IISER Mohali.Stated in his Y Combinator founder profile.^[4]
2. 2010sStudies for a bachelor's degree at the Indian Institute of Science Education and Research, Mohali, then a master's degree at Carnegie Mellon University in Pittsburgh.The Y Combinator profile gives the two degrees and the two institutions.^[4]
3. 2010s to 2020sWorks as a cancer genomics researcher at Stanford, Yale, Carnegie Mellon and the Max Planck Institute.Confirmed in the company's funding coverage.^[1]^[2]
4. 2020sJoins Sanofi, including its Genomic Medicine Unit, according to the employer history on his founder profile.No job title or dates are published.^[4]
5. 2020sWorks as an early researcher with AI laboratories on reinforcement learning tasks and benchmarks in healthcare and biotechnology.He describes the work this way; the labs are not named.^[2]^[4]
6. 2025Co-founds BioStack with Parth Patwa in San Francisco. Patwa is chief technology officer.Reported by Indian Startup News and Bharat Fast.^[1]^[2]
7. 2026BioStack is part of Y Combinator's Spring 2026 batch and grows to a team of 11.Team size as reported at the time of the funding.^[2]
8. 2026On 22 October the company announces a $9.5 million seed round led by Peak XV, DCVC and Afore Capital. Four days later Indian media report the round.The announcement carries the 22 October date and the full investor list.^[3]

Who Sanat Mishra is

Sanat Mishra is the co-founder and chief executive of BioStack, a healthcare data company he started in 2025 with Parth Patwa. The company sits at the point where hospitals, medical records and artificial intelligence meet. It collects clinical information that health systems already hold, links it into a timeline for each patient, removes identifying details, and sells the resulting datasets to companies training medical models.^[1][2]

His route into that business ran through research rather than through software. Before BioStack he worked in cancer genomics at four institutions, spent time at Sanofi's genomic medicine unit, and did early work with AI laboratories on reinforcement learning tasks for healthcare and biotechnology. That mix, a scientist who has handled clinical data and an engineer who has worked on model training, is the credential the company sells to investors.^[2][4]

He is not a public figure in the way a consumer startup founder often is. There is no published date of birth, no interview about his family, and no personal social media presence cited in the coverage of the funding round. The record that exists is professional: degrees, laboratories, employers, a company and a round.^[1][2][4]

Mumbai, IISER Mohali and Carnegie Mellon

Mishra describes himself as hailing from Mumbai. In his own account on the Y Combinator founder page he writes that he attended IISER Mohali for a bachelor's degree and Carnegie Mellon for a master's, and that he came to the United States from Mumbai. The two institutions explain the shape of the career that followed: IISER Mohali is one of India's research-focused science schools, and Carnegie Mellon is one of the centres of machine learning and computational biology in the United States.^[4]

The founder profile does not say which subject each degree was in, and neither the company nor the coverage of the funding round fills that gap. What can be said is that the move from a science education in India to a graduate degree in Pittsburgh is a common route into American computational research, and that Mishra took it before he had founded anything.^[4]

Carnegie Mellon appears twice in his history. It is where he took his master's degree, and it is also one of the four institutions where he did cancer genomics research. That overlap matters for BioStack's pitch, because the company is not selling generic software. It is selling access to data that has been structured by people who have worked with genomic and clinical records at a research level.^[2][4]

Cancer genomics in four laboratories

The research career that Mishra describes spans Stanford, Yale, Carnegie Mellon and the Max Planck Institute. Cancer genomics is the study of the changes in a tumour's DNA and RNA, and it depends on paired data: the molecular profile of a cancer, the treatment a patient received, and what happened afterwards. That is precisely the kind of linked, longitudinal record that BioStack now says it builds at scale.^[2][3]

Indian Startup News and Bharat Fast both describe the four institutions in the same terms, which suggests the wording comes from the company's own materials. Neither outlet names a laboratory, a principal investigator, a publication or a period of employment. The claim is therefore best read as a summary of his research history supplied by Mishra and repeated by the press, not as a verified academic record.^[1][2]

What the research background does explain is the company's vocabulary. BioStack talks about biomarker discovery, patient stratification and treatment response analysis. These are the questions a cancer genomics researcher asks of a cohort, and they are the questions the company says its datasets are designed to answer for buyers.^[3][5]

Sanofi and the move into industry

The Y Combinator profile lists Sanofi, including the Genomic Medicine Unit, among the places where Mishra worked before founding BioStack. Sanofi is a French multinational pharmaceutical company, and its genomic medicine unit works on treatments built around genetic and molecular evidence. For a cancer genomics researcher, it is a natural move from academic laboratories into drug development.^[4]

No title, date or description of the work has been published. The employer history is the only public trace, and it is thin. What it establishes is that Mishra has seen clinical and genomic data from the inside of a large drug company as well as from university laboratories, which is relevant to a business whose customers include biotech companies and AI developers.^[4]

That experience also sits behind one of the more specific claims in BioStack's announcement. The company says its datasets connect biological and clinical data with treatment histories and long term outcomes, so that researchers can see what happened to a patient and how different interventions affected their health over time. That is a pharmaceutical research question stated as a data product.^[3]

Reinforcement learning and healthcare benchmarks

Mishra says he worked as an early researcher with AI laboratories on reinforcement learning tasks and benchmarks across healthcare and biotechnology. Reinforcement learning is the branch of machine learning in which a model learns by acting and receiving a reward, rather than by copying labelled examples. In medicine the appeal is obvious, because a model that can reason through a patient's history step by step is closer to how a clinician works than a model that only classifies an image.^[2][4]

The company's product page reflects that interest. BioStack advertises reinforcement learning environments for post-training, alongside ready-made datasets, annotation of public or novel data, and multi-agent reasoning infrastructure. In plain terms, it sells both the data and the practice ground on which a medical model can be trained and tested.^[5]

The link between the research claim and the product is the reason the funding round was possible. Investors in medical AI have become wary of models that perform well on a benchmark but badly in a hospital, and the argument for BioStack is that the bottleneck is not the model but the data underneath it. Mishra's own experience of building benchmarks is part of that argument.^[2][3]

Why he started BioStack

BioStack was founded in 2025, according to both Indian Startup News and Bharat Fast. The company's starting observation is simple. Patient information in most health systems sits in separate places: doctors' notes in one system, laboratory results in another, scans in a third, and none of them arranged in a way a model can use. A patient's history is therefore spread across software that does not talk to itself.^[1][2]

BioStack's answer is to pull those sources into a longitudinal record that follows the patient over time, linking clinical notes, laboratory results, medical imaging, medications, treatment histories and outcomes into one timeline. Once that record is de-identified, it becomes training material for research, drug development and healthcare AI. The company lists disease modelling, biomarker discovery, patient stratification and treatment response analysis as uses.^[3]

The commercial logic is that hospitals sit on records they cannot easily use. Storing them is a cost, research access is slow, and most hospitals have no in-house team to structure the data for AI. BioStack offers to do that work and share the value. For a provider, the pitch is that dead storage becomes a research partnership. For a model developer, the pitch is that the hardest part of medical AI is not compute but clean, legally sourced, longitudinal data.^[1][2]

The $9.5 million seed round

BioStack announced a $9.5 million seed round on 22 October 2026. The round was led by Peak XV, DCVC and Afore Capital, with participation from Afore Capital, DCVC, Emerson Collective, SV Angel, Verdict Capital, Streamlined Ventures and Y Combinator. The company did not disclose its valuation, then or since.^[1][3]

The money is earmarked for expansion across the United States and international markets, development of the technology platform, and hiring for engineering and research. At the time of the announcement the company had a team of 11 and had just come through Y Combinator's Spring 2026 batch.^[2][3]

Pushpak Kedia, a vice president at Peak XV, gave the investor's version of the thesis in the announcement. He said the next frontier of healthcare AI would depend not only on better models but on access to high quality, longitudinal data that reflects how patients are treated over time, and described BioStack as potentially an important data layer for the next generation of medical AI.^[3]

What the platform actually does

The company says its network spans the United States, India, Brazil and Argentina, with access to more than 100 million de-identified patient records and relationships with hospitals in all four countries. It says it has combined several hundred thousand X-rays, MRI and CT scans with several million telehealth audio transcripts, plus pathology and other clinical records.^[2][3]

That mix of data types is the product's selling point. Clinical AI agents are expected to work from notes, scans, laboratory values and conversations rather than from a single test, because a real diagnosis rarely comes from one source. BioStack's claim is that it can supply multimodal records that are linked to outcomes, which is what a model needs in order to learn how a disease progresses.^[3][5]

The company also says its platform includes workflows built around each provider's own data privacy protocols rather than a single global pipeline. That detail matters commercially. De-identification rules differ between the United States, India, Brazil and Argentina, and a vendor that cannot demonstrate local compliance cannot sign a hospital in any of them.^[1][3]

The India cancer vaccine programme

In India, BioStack says it is helping connect cancer patients with an investigational cancer vaccine programme. The clinical information of participating patients supports the development work of biotech companies, and eligible patients may get access to personalised investigational treatments.^[2][3]

The company did not name the biotech firm or the vaccine. That silence is normal at this stage of a trial, but it also means the arrangement cannot be verified beyond BioStack's own statement. What the company has described is a model in which patient data and patient access move in the same transaction: the data helps develop a treatment, and some patients may receive it.^[3]

For Mishra, the Indian programme is the clearest example of the argument he makes about the company. India has a large patient population, a growing biotech sector and hospitals that generate records in volume. If the data can be structured and de-identified to the standard a regulator accepts, the country becomes both a source of training data and a place where the resulting treatments can be tested.^[2][3]

The market he is selling into

Healthtech funding has been consolidating. Startups in the sector raised $22.8 billion across 1,150 rounds in 2026 up to the date of the BioStack announcement, against $19.9 billion across 1,530 rounds in the same period of 2025, according to Tracxn data cited in the coverage. That is roughly 15 per cent more capital in about 25 per cent fewer deals.^[1][2]

BioStack is on the right side of that shift. Larger rounds going to fewer companies favour a business that needs capital to sign hospitals and build data infrastructure, and the company's investor list includes funds that can follow on. The risk is the other side of the same trend: a data business that does not name customers is hard to underwrite, and the round was announced without a named hospital group or biotech partner.^[1]

The company's own announcement is candid about the size of the claim and vague about the evidence. It says it has access to more than 100 million records and works with hospitals in four countries, but it does not name them, publish a benchmark or describe how many records are complete enough to train on. Those are the questions a buyer or a journalist would ask next.^[3]

What has not been confirmed

Several basic personal facts about Sanat Mishra are not public. No date of birth, age, height, family detail or marital status appears in any of the sources used for this entry, and none has been inferred here. His schooling before IISER Mohali is not recorded.^[1][2][4]

The research record is also incomplete. The claim that he worked at Stanford, Yale, Carnegie Mellon and the Max Planck Institute comes from the company and is repeated by two outlets, but no laboratory, supervisor, publication or date range is given. The Sanofi role is listed only as an employer on his Y Combinator profile, without a title. No peer reviewed paper under his name has been identified in the sources for this entry, and none is claimed.^[2][4]

On the company, the valuation was not disclosed, the hospital partners are not named, revenue and losses are not public, and the Indian biotech partner in the cancer vaccine programme is unnamed. The team size of 11 is as reported at the time of the funding announcement and may have changed. The gap between a founding year of 2025 and a place in Y Combinator's Spring 2026 batch is what the sources say, and no source explains the timing.^[1][2][3]